Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEKTAR THERAPEUTICS

(NKTR)
  Report
Delayed Quote. Delayed Nasdaq - 10/26 04:00:00 pm
16.25 USD   +0.81%
10/25INSIDER SELL : Twist Bioscience
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
16.24(c) 16.56(c) 16.35(c) 16.12(c) 16.25 Last
626 033 590 997 406 801 562 545 569 816 Volume
-2.52% +1.97% -1.27% -1.41% +0.81% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 109 M - -
Net income 2021 -552 M - -
Net cash position 2021 484 M - -
P/E ratio 2021 -5,39x
Yield 2021 -
Sales 2022 373 M - -
Net income 2022 -356 M - -
Net cash position 2022 418 M - -
P/E ratio 2022 -8,56x
Yield 2022 -
Capitalization 2 987 M 2 987 M -
EV / Sales 2021 22,9x
EV / Sales 2022 6,88x
Nbr of Employees 718
Free-Float 99,1%
More Financials
Company
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages... 
More about the company
Ratings of Nektar Therapeutics
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about NEKTAR THERAPEUTICS
10/25INSIDER SELL : Twist Bioscience
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
09/23Redhill Biopharma, AstraZeneca, Nektar Therapeutics Settle Movantik Patent Litigation w..
MT
09/22NEKTAR THERAPEUTICS : Thinking about trading options or stock in Ambarella, Robinhood Mark..
PR
09/21Nektar Therapeutics Shares Rise 5% on Deal With Pfizer, Merck KGaA
DJ
09/21NEKTAR THERAPEUTICS : Partners With Pfizer, Merck for Clinical Trial
MT
09/21NEKTAR THERAPEUTICS : Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germ..
PR
09/21Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfiz..
CI
09/17NEKTAR THERAPEUTICS : Corporate Presentation September 2021
PU
08/18INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Nektar Therapeutics
MT
08/18INSIDER TRENDS : Nektar Therapeutics Insider Extends 90-Day Selling Trend
MT
08/18INSIDER TRENDS : Selling By Insiders Lingers at Nektar Therapeutics
MT
08/06NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/05Nektar Therapeutics Provides Revenue Guidance for the Full Year 2021
CI
More news
News in other languages on NEKTAR THERAPEUTICS
10/22BB BIOTECH : Gewinnrealisierungen -2-
09/23Redhill Biopharma, AstraZeneca, Nektar Therapeutics règlent le litige relatif au brevet..
09/21Nektar Therapeutics s'associe à Pfizer et Merck pour un essai clinique
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
More news
Analyst Recommendations on NEKTAR THERAPEUTICS
More recommendations
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | MarketScreener
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 16,25 $
Average target price 29,50 $
Spread / Average Target 81,5%
EPS Revisions
Managers and Directors
Howard W. Robin President, Chief Executive Officer & Director
Gilbert M. Labrucherie Chief Operating & Financial Officer
Robert B. Chess Chairman
Jonathan Zalevsky Chief Research & Development Officer
Dimitry S. A. Nuyten Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS-5.18%2 963
MODERNA, INC.234.60%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.43.58%49 145
SEAGEN INC.0.22%31 933
CELLTRION, INC.-38.02%25 328